<DOC>
	<DOCNO>NCT00905762</DOCNO>
	<brief_summary>The purpose study assess concentration besifloxacin compare gatifloxacin moxifloxacin human conjunctival tissue , follow single drop drug instill topically study eye . Conjunctival biopsy perform specified time point , follow use loteprednol etabonate/tobramycin ophthalmic suspension four time day 5 day .</brief_summary>
	<brief_title>Concentration Besifloxacin , Gatifloxacin , Moxifloxacin Human Conjunctiva After Topical Instillation</brief_title>
	<detailed_description />
	<mesh_term>Gatifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>7- ( 3-aminohexahydro-1H-azepin-1-yl ) -8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Willing avoid disallow medication appropriate washout period . Have best correct visual acuity 0.60 logMAR good eye measure use ETDRS chart . Have know allergy and/or sensitivity test article component therapy associate trial . Monocular . Have previously participate conjunctival biopsy study . Be currently enrol investigational drug device study use investigational drug device within 30 day entry study . condition situation investigator feel may put subject significant risk , may confound study result , may interfere significantly subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>pharmacokinetics</keyword>
</DOC>